NanoDOX is under clinical development by Ology Bioservices and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NanoDOX’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NanoDOX is under development for the treatment of atopic dermatitis. The drug candidate contains 1 percentage doxycycline monohydrate hydrogel. It is applied topically as a gel. It acts by targeting matrix metalloproteinase (MMP).
It was under development for the treatment of dermal ulcers such as diabetic ulcers of the foot and lower limbs, trauma and surgical wounds.
Ology Bioservices overview
Ology Bioservices is an US based integrated biopharmaceutical company. The company provides contract development and manufacturing services. The company manufactures biopharmaceutical products which include vaccines, antibodies, protein therapies and medical devices.
For a complete picture of NanoDOX’s drug-specific PTSR and LoA scores, buy the report here.